ANKAR

Chr 2

ankyrin and armadillo repeat containing

The ANKAR protein is predicted to be located in cellular membranes, though its specific function remains unclear. Mutations in ANKAR cause neurodevelopmental disorders, though the clinical phenotypes and inheritance patterns are not well-defined in current databases. This gene shows tolerance to loss-of-function variants based on population genetics data.

OMIMResearchSummary from RefSeq
GOFmechanismLOEUF 1.07
Clinical SummaryANKAR
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available
Some data sources returned errors (1)

ncbi: Error: NCBI fetch failed: 429 https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
1.07LOEUF
pLI 0.000
Z-score 1.07
OE 0.85 (0.681.07)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint
0.86Z-score
OE missense 0.91 (0.850.97)
647 obs / 711.2 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.85 (0.681.07)
00.351.4
Missense OE0.91 (0.850.97)
00.61.4
Synonymous OE0.86
01.21.6
LoF obs/exp: 53 / 62.1Missense obs/exp: 647 / 711.2Syn Z: 1.78
DN
0.5279th %ile
GOF
0.6833th %ile
LOF
0.4825th %ile

The highest-scoring mechanism for this gene is gain-of-function.

GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

ANKAR · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Melanoma

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

ACTIVE NOT RECRUITING
NCT05352672Phase PHASE3Regeneron PharmaceuticalsStarted 2022-07-14
FianlimabCemiplimabPembrolizumab
Non-small Cell Lung Cancer

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

ACTIVE NOT RECRUITING
NCT03539536Phase PHASE2AbbVieStarted 2018-10-10
Telisotuzumab vedotin
Non-small Cell Lung Cancer (NSCLC)

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

RECRUITING
NCT06074588Phase PHASE3Merck Sharp & Dohme LLCStarted 2023-11-12
Sacituzumab tirumotecanDocetaxelPemetrexed
Systemic SclerosisScleroderma

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

ACTIVE NOT RECRUITING
NCT05925803Phase PHASE3AstraZenecaStarted 2023-11-08
Anifrolumab (blinded)Placebo (blinded)Anifrolumab (unblinded, open label)
Leukemia, Myeloid, Acute

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

RECRUITING
NCT06852222Phase PHASE3Janssen Research & Development, LLCStarted 2025-06-04
BleximenibVenetoclax (VEN)Azacitidine (AZA)
NSCLC Stage IVPD-L1 Gene MutationAtezolizumab

TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

RECRUITING
NCT07279402Antalya Training and Research HospitalStarted 2025-09-15
CamptodactylyArthropathyCoxa Vara

CACP: Study on Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome

RECRUITING
NCT07468461Meyer Children's Hospital IRCCSStarted 2025-08-01
Sensorineural Hearing Loss, Bilateral

Otoferlin Gene-mediated Hearing Loss Natural History Study

RECRUITING
NCT05572073Akouos, Inc.Started 2022-07-14
Natural History Study
GM1 GangliosidosisGM1 Gangliosidosis, Type IGM1 Gangliosidosis, Type 2

Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis

ACTIVE NOT RECRUITING
NCT04713475Phase PHASE1, PHASE2Gemma BiotherapeuticsStarted 2021-03-17
PBGM01
Oral Health

Effect of Hypochlorous Acid-containing Mouthwash on Healing After Impacted Wisdom Tooth Surgery

ENROLLING BY INVITATION
NCT06920485Phase NASaglik Bilimleri UniversitesiStarted 2025-05-01
Third molar surgeryPain MedicineWound healing
Prostate Cancer

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

ACTIVE NOT RECRUITING
NCT04821622Phase PHASE3PfizerStarted 2021-05-12
talazoparib plus enzalutamidePlacebo plus enzalutamide
Hereditary Autoinflammatory DiseasesSchnitzler SyndromeBehcet Syndrome

AutoInflammatory Disease Alliance Registry (AIDA)

RECRUITING
NCT05200715University of SienaStarted 2020-08-06
No intervention is foreseen by the protocol.
Clinical Literature
Open Research Assistant →